Ingredient study / 01
GHK-Cu: start with the form.
This guide explains GHK-Cu, a short chain of protein building blocks bound to copper. The first distinction is simple: a skincare ingredient placed on the skin and a substance proposed for injection have different evidence and different rules.
Licensed U.S. provider review
Start a Promise Peptides GHK-Cu visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider reviews every request and decides whether a prescription is appropriate. Not everyone qualifies. Compounded medicines are made to order. They are not approved by the U.S. Food and Drug Administration (FDA).
U.S. patients only. Availability varies by state and by treatment.
The name, unpacked
A small chain, holding copper
A peptide is a short chain of amino acids, the building blocks of proteins. GHK has three: glycine, histidine and lysine. GHK-Cu is that chain bound to copper. “Cu” is the chemical symbol for copper.
GHK occurs naturally in the body. That fact describes its origin. It does not establish that a prepared product, especially an injection, is safe.
Copper Tripeptide-1 is a name used for GHK-Cu in skincare. “Tripeptide” means a peptide with three building blocks. A name in an ingredient list does not tell us the quality of the finished product.
The distinction that matters
On skin is not the same as injected
Topical skincare
Topical means put on the skin. Copper Tripeptide-1 is used in cosmetic creams and serums. Most cosmetics do not need approval by the U.S. Food and Drug Administration (FDA) before sale. The claims made about a product can also affect whether it falls under drug rules.
An injectable drug
Injectable means intended for injection into the body. FDA has not approved a GHK-Cu medicine. Evidence about a cosmetic cannot establish the safety of this route.
Reading the evidence
Much of the research is early
Researchers have studied GHK-Cu in cells grown in lab dishes and in animals. Human research is mainly small studies of products placed on the skin. Small studies leave many safety questions open.
A study has to be read with its form and subjects in mind. Work on isolated skin in a lab is not the same as a trial in people. Work on a cream is not a trial of an injection.
FDA says human safety data for injectable GHK-Cu are limited. It also flags a risk of immune reactions, meaning the body's defenses reacting to the product. Its concerns include peptides clumping together and unwanted material in a preparation.
What the FDA record says
On FDA's page current as of April 22, 2026, injectable GHK-Cu is listed as “nominated but withdrawn.” The groups seeking its review took back their requests. Withdrawal is not clearance, approval or permission to compound it. FDA gives no date for that withdrawal.
Non-injected GHK-Cu has a separate entry in Category 1 on FDA's list updated May 14, 2026. That means FDA generally does not plan to act against a pharmacy under set conditions while review continues. It is not approval. It does not include injections.
What a provider has to consider
A product name is only the beginning. A provider considers whether any prescription is appropriate; a pharmacy separately considers whether it can lawfully prepare it.
- Which form is being discussed: skincare or a proposed drug?
- What human evidence applies to that exact form?
- What safety questions remain, and what follow-up would be needed?
- Can the ingredient lawfully be used in that preparation?
Sources for this page
- A research review of topical GHKMortazavi and colleagues · Bioimpacts, 2025 · PMID 39963574
- FDA's peptide safety concerns and withdrawn requestsU.S. Food and Drug Administration
- FDA's separate category entry for non-injected GHK-CuU.S. Food and Drug Administration · List updated May 14, 2026
- How FDA rules for cosmetics differ from drug rulesU.S. Food and Drug Administration
The next page is yours
Keep the licensed route in view
A visit begins a review. A licensed U.S. provider decides whether a prescription is appropriate. Not everyone qualifies, and availability varies by state and by treatment.
Licensed U.S. provider review
Start a Promise GHK-Cu visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider is a health professional who can make prescription decisions. One reviews every request and decides whether to prescribe. Not everyone qualifies.
Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved. A pharmacy separately decides whether it can lawfully prepare a prescription.
U.S. patients only. Availability varies by state and by treatment.
Promise is LegitScript-certified. That certification is not FDA approval.